BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun X, Li L, Lyu N, Mu L, Lai J, Zhao M. Follow-up schedule for initial recurrent hepatocellular carcinoma after ablation based on risk classification. Cancer Imaging 2020;20:42. [PMID: 32611383 DOI: 10.1186/s40644-020-00319-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Nam D, Chapiro J. Machine Learning-Based Surveillance Strategy after Complete Ablation of Initially Recurrent Hepatocellular Carcinoma: Worth the Risk? J Vasc Interv Radiol 2021;32:1558-9. [PMID: 34717834 DOI: 10.1016/j.jvir.2021.08.014] [Reference Citation Analysis]
2 Sun X, Yang Z, Mei J, Lyu N, Lai J, Chen M, Zhao M. The guiding value of microvascular invasion for treating early recurrent small hepatocellular carcinoma. Int J Hyperthermia 2021;38:931-8. [PMID: 34121576 DOI: 10.1080/02656736.2021.1937715] [Reference Citation Analysis]
3 Hu S, Wu X, Wei M, Ling Y, Zhu M, Wang Y, Chen Y, Jin M, Peng Z. Cost-Effectiveness Analysis of Follow-Up Schedule for Hepatocellular Carcinoma after Radiofrequency Ablation. J Oncol 2022;2022:3569644. [PMID: 35345515 DOI: 10.1155/2022/3569644] [Reference Citation Analysis]
4 Mocan T, Nenu I, Crăciun R, Spârchez Z. Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare? J Gastroenterol Hepatol 2021;36:1518-28. [PMID: 33326142 DOI: 10.1111/jgh.15376] [Reference Citation Analysis]